指南导向预防与小儿术后恶心呕吐关联的单中心回顾性队列研究
本研究为单中心回顾性队列,纳入2018至2021年14,747例小儿全麻病例,按MPOG PONV-04指标定义充分预防。贝叶斯模型加权后,充分预防与PONV发生率降低相关(加权中位OR 0.82,95%CrI 0.66-1.02;获益概率0.97),加权边际绝对风险降低1.3%(-0.1%至3.1%)。结论认为指南导向预防与PONV的关联在风险谱上不一致。
要点
- 充分预防组PONV发生率为9%,不充分组为12%。
- 加权后充分预防与PONV降低相关,OR 0.82,获益概率0.97。
- 3个及以上危险因素时加用第三种止吐药未进一步降低风险。
核心结论
- 指南导向的PONV预防与PONV发生率之间的关联在指南定义的风险谱上不一致。
- 二分类危险因素求和忽略了各组成部分的差异效应,且这些危险因素之外可能存在预后信息。
- 给定危险因素总和下的PONV风险并非同质,而由危险因素的独特构成和其他预后特征决定。
研究设计与样本
- 单中心回顾性研究,纳入2018至2021年小儿全麻病例。
- 共纳入14,747例病例。
- 采用贝叶斯二项模型配合倾向评分加权分析非随机分配的充分预防。
主要发现
- 总体PONV发生率为11%,充分预防组为9%,不充分组为12%。
- 加权中位比值比0.82(95%可信区间0.66-1.02),获益概率0.97。
- 加权边际绝对风险降低1.3%(-0.1%至3.1%)。
- 未加权估计中,1至2个危险因素患者充分预防与PONV降低相关(获益概率0.96和0.95),3个及以上危险因素患者充分预防与PONV增加相关(3、4、5个危险因素的获益概率分别为0、0.01、0.03)。
- 加权后1至2个危险因素持续获益(获益概率0.90和0.94),3个及以上危险因素风险均衡化。
关键数值与推荐
- MPOG定义的PONV危险因素:年龄≥3岁、挥发性麻醉药使用≥30分钟、PONV史、长效阿片类药物、女性≥12岁、高风险手术。
- 充分预防按MPOG PONV-04指标定义:1个危险因素用1种止吐药,2个危险因素用2种,3个及以上危险因素用3种。
- PONV定义为记录到术后恶心/呕吐或给予补救止吐药。
临床怎么用
- 临床可参考MPOG PONV-04指标进行小儿PONV预防,但需注意其与结局的关联随危险因素数量不同而异。
- 对于3个及以上危险因素患者,加用第三种止吐药在加权后未显示进一步降低PONV风险。
- 评估PONV风险时应考虑危险因素的具体构成而非仅看数量总和。
局限性
- 单中心回顾性研究设计。
- 充分预防为非随机分配。
- 未加权估计中3个及以上危险因素的结果在加权后发生改变,提示可能存在混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines for postoperative nausea and vomiting (PONV) prophylaxis in pediatric patients recommend escalation of the number of antiemetics based on a preoperative estimate of PONV risk. These recommendations have been translated into performance metrics, most notably by the Multicenter Perioperative Outcomes Group (MPOG), used at over 25 children's hospitals. The impact of this approach on clinical outcomes is not known. METHODS: We performed a single-center, retrospective study of pediatric general anesthetic cases from 2018 to 2021. PONV risk factors were defined using MPOG definitions: age ≥3 years, volatile use ≥30 minutes, PONV history, long-acting opioids, female ≥12 years, and high-risk procedure. Adequate prophylaxis was defined using the MPOG PONV-04 metric: 1 agent for 1 risk factor, 2 agents for 2 risk factors, and 3 agents for 3+ risk factors. PONV was defined as documented postoperative nausea/emesis or administration of a rescue antiemetic. Given the nonrandomized allocation of adequate prophylaxis, we used Bayesian binomial models with propensity score weighting. RESULTS: A total of 14,747 cases were included, with PONV in 11% (9% adequate prophylaxis versus 12% inadequate). Overall, there was evidence for reduced incidence of PONV with adequate prophylaxis: weighted median odds ratio 0.82 (95% credible interval, 0.66-1.02; probability of benefit, 0.97) and weighted marginal absolute risk reduction 1.3% (-0.1% to 3.1%). In unweighted estimates, there was an interaction between sum of risk factors and the association of adequate prophylaxis with PONV, with reduced incidence in patients with 1 to 2 risk factors (probability of benefit 0.96 and 0.95) but increased incidence in patients with 3+ risk factors receiving adequate prophylaxis (probability of benefit 0, 0.01, and 0.03 for 3, 4, and 5 risk factors). This was attenuated by weighting, with persistent benefit in 1 to 2 risk factors (probability of benefit 0.90 and 0.94) but equalization of risk in 3+ risk factors. CONCLUSIONS: Guideline-directed PONV prophylaxis is inconsistently associated with incidence of PONV across the guideline-defined risk spectrum. This phenomenon, and its attenuation with weighting, is consistent with 2 points: dichotomous risk-factor summation ignores differential effects of individual components, and prognostic information might exist beyond these risk factors. PONV risk at a given sum of risk factors is not homogeneous, but rather is determined by the unique composition of risk factors and other prognostic attributes. These differences appear to have been identified by clinicians, prompting use of more antiemetics. Even after accounting for these differences, however, addition of a third agent did not further reduce risk.
引用
- Andrew BY, Habib AS, Taicher BM, et al. The Association of Guideline-Directed Prophylaxis with Postoperative Nausea and Vomiting in Pediatric Patients: A Single-Center, Retrospective Cohort Study. Anesth Analg. 2024. PMID: 37235529. doi:10.1213/ANE.0000000000006543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。